Tests MBX 4291 safety in adults with obesity
Tests a new drug, MBX 4291, for safety in adults with obesity.
Key facts
- Who runs it
- MBX Biosciences
- Where
- Doral, Kansas City, Knoxville, and Lexington, United StatesSee the 4 sites
- Trial code
- Registry title
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 124 people, planned
- Started
- 3 Sept 2025
- Planned end
- 30 Oct 2026
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- MBX 4291
- Placebo
- Record updated
- 9 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity who have kept a stable weight. It tests the safety of a new drug, MBX 4291, given as injections under the skin.
- Age
- Older than 18 and up to 65 years.
- Sex
- All sexes can join.
- Disease stage
- Obesity with a BMI of 30 or more but under 50 kg/m2 at screening and baseline.
Main reasons for not taking part
- Significant illness or medical disorder that the investigator thinks would stop you taking part
- Current or past pancreatitis, type I or type II diabetes
- Obesity with a secondary cause, for example hypothalamic, monogenic, syndromic or endocrine causes
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Body weight change of more than 5% in the 3 months before screening or between screening and baseline
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age of >18 to ≤65 years at the time of signing the informed consent
- Has a BMI of ≥30 to <50 kg/m2 at screening and baseline
- Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline
Who cannot take part
- History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study
- History of currently active pancreatitis, type I and type II diabetes
- A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Doral, FloridaHospital not named in the registryContact: Elisa Fabbrini, MD, PhDTaking people
- Kansas City, MissouriHospital not named in the registryContact: Elisa Fabbrini, MD, PhDTaking people
- Knoxville, TennesseeHospital not named in the registryContact: Elisa Fabbrini, MD, PhDTaking people
- Lexington, KentuckyHospital not named in the registryContact: Elisa Fabbrini, MD, PhDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
The 4 groups in the trial
- MBX 4291 (Part A)Treatment being tested
Participants will be administered single ascending doses of MBX 4291, or matching placebo.
Treatment: MBX 4291
- MBX 4291 (Part B)Treatment being tested
Participants will be administered multiple ascending doses of MBX 4291, or matching placebo.
Treatment: MBX 4291
- MBX 4291 (Part C)Treatment being tested
Participants will be administered multiple ascending doses of MBX 4291, or matching placebo.
Treatment: MBX 4291
- PlaceboPlacebo, for comparison
Participants will be administered single or multiple ascending doses of placebo.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized, Double-blind, Placebo-controlled First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MBX 4291 in Adult Participants With Obesity
- Plain-language title
- Tests MBX 4291 safety in adults with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07142707, who can take part
- Record updated
- 9 June 2026